Cytokine genotype polymorphisms in breast carcinoma: Associations of TGF-β1 with relapse

Cancer Investigation

Volumn 23, Issue 3, 2005, Pages 208-214

  Skerrett, Donna L ^a   Moore, Ellery M ^a   Bernstein, David S ^a   Vahdat, Linda ^b  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Breast cancer; Cytokine polymorphisms; TGF 1

Indexed keywords

CYTOKINE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; PROGESTERONE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANGIOGENESIS; ARTICLE; AUTOIMMUNE DISEASE; BREAST CARCINOMA; CANCER GENETICS; CANCER RELAPSE; CASE CONTROL STUDY; CELL PROLIFERATION; CODON; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENOTYPE; HUMAN; IMMUNOGENETICS; INTRON; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL; CARCINOMA, LOBULAR; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; GENOTYPE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-6; LYMPH NODES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PLOIDIES; POLYMORPHISM, GENETIC; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 20044383217     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-200055954     Document Type: Article

References (32)

1. NCCN Proceedings. NCCN practice guidelines for the treatment of breast cancer. Oncology 1999, 13, 187-212.
2. Styblo, T.M.; Wood, W.C. Adjuvant chemotherapy in the node-negative breast cancer patient. Surg. Clin. North Am. 1996, 76, 327-341.
3. Eissa, S.; Labib, R.; Khalifa, A.; Swelam, N.; Khalil, F.; Megeid El-Shenawy, A. Regulators of apoptosis in human breast cancer. Clin. Biochem. 1999, 32, 321-326.
4. Meyer, J.S.; Fahrner, M.; Daniel, F.C. Pathology and behavior of small breast carcinomas. Sem. Diag. Pathol. 1999, 16, 257-268.
5. Rudolph, P.; Olsson, H.; Bonatz, G.; Ratjen, V.; Bolte, H.; Baldetorp, B.; Ferno, M.; Parwaresch, R.; Alm, P. Correlation between p53, c-erbB-2, and topoisomerase IIa expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. J. Pathol. 1999, 187, 207-216.
6. Gasparini, G.; Toi, M.; Gion, M.; Verderio, P.; Dittadi, R.; Hanatani, M.; Matsubara, I.; Vinante, O.; Bonoldi, E.; Boracchi, P.; Gatti, C.; Suzuki, H.; Tominaga, T. Prognostic significance of vascular endothelial growth factor in node-negative breast carcinoma. J. Natl. Cancer Inst. 1997, 89, 139-147.
7. Garrido, F.; Ruiz-Cabello; Cabrera, T.; Perez-Villar; Lopez-Botet, M.; Duggan-Keen, M.; Stern, P. Implications for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol. Today 1997, 82, 88-94.
8. http://bris.ac.uk/pathandmicro/services/GA1/cytokine4.htm
9. Daser, A.; Mitchison, H.; Mitchison, A.; Muller, B. Non-classical MHC genetics of immunological disease in man and mouse: the role of proinflammatory cytokines. Cytokine 1996, 8, 593-597.
10. Turner, D.; Grant, S.C.D.; Yonan, N.; Sheldon, S.; Dyer, P.A.; Sinnott, P.J.; Hutchinson, I.V. Cytokine gene polymorphism and heart transplant rejection. Transplantation 1997, 64, 776-779.
11. Hutchinson, I.V.; Turner, D.M.; Sankaran, D.; Awad, M.R.; Sinnott, P.J. Influence of cytokine genotypes on allograft rejection. Transplant. Proc. 1998, 30, 862-863.
12. Middleton, P.G.; Taylor, P.R.A.; Jackson, G.; Proctor, S.J.; Dickinson, A.M. Cytokine gene polymorphisms associating with severe graft versus host disease in HLA identical sibling transplants. Blood 1998, 92, 3943-3948.
13. Cavet, J.; Dickinson, A.; Norden, J.; Taylor, P.R.A.; Jackson, G.H.; Middleton, P.G. Interferon g and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood 2001, 98, 1594-1600.
14. Kuninaka, S.; Yano, T.; Yokoyama, H.; Fukuyama, Y.; Terazaki, Y.; Uehara, T.; Kanematsu, T.; Asoh, H.; Ichinose, Y. Direct influences of pro-inflammatory cytokines (IL-1b, TNF-a, IL-6) on the proliferation and cell surface antigen expression of cancer cells. Cytokine 2000, 12, 8-11.
15. Ballen, K.; Hicks, J.; Dharan; Ambruso, D.; Anderson, K.; Bianco, C.; Bermiller, L.; Dickey, W.; Lottenberg, R.; O'Neill, M.; Popocsky, M.; Skerrett, D.; Sniecinski, I.; Wingard, J. Racial and ethnic composition of volunteer cord blood donors: comparison with volunteer unrelated marrow donors. Transfusion 2002, 42, 1279-1284.
16. Couchane, L.; Ahmed, S.B.; Baccouche, S.; Remadi, S. Polymorphism in the tumor necrosis factor a promoter region and in the heat shock protein 70 genes associated with malignant tumors. Cancer 1997, 80, 1489-1496.
17. Fleiss, J.L. Determining sample sizes needed to detect a difference between two proportions. In Statistical Methods for Rates and Proportions, 2nd Ed.; Fleiss, J.L., Ed.; Wiley Series in Probability and Mathematical Statistics: New York, 1981; 33-49.
18. Densem, C.G.; Hutchinson, I.V.; Cooper, A.; Yonan, N.; Brooks, N.H. Polymorphism of the transforming growth factor beta-1 gene correlates with the development of coronary vasculopathy following cardiac transplantation. J. Heart Lung Transplant. 2000, 19, 551-556.
19. Sankaran, D.; Asderakis, A.; Ashraf, S.; Roberts, I.S.D.; Short, C.D.; Dyer, P.A.; Sinnott, P.J.; Hutchinson, I.A. Cytokine gene polymorphisms predict acute graft rejection following renal transplantation. Kidney Int. 1999, 56, 281-288.
20. Zheng, C.; Huang, D.R.; Bergenbrant, S.; Sundblad, A.; Osterborg, A.; Bjorkholm, M.; Holm, G.; Yi, Q. Interleukin-6, tumor necrosis factor-a, interleukin-1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br. J. Hematol. 2000, 109, 39-45.
21. Pravica, V.; Asderakis, A.; Perry, C.; Hajeer, A.; Sinnott, P.J.; Hutchinson, I.V. In vitro production of IFN-g correlates with CA repeat polymorphisms in the human IFN-gamma gene. Eur. J. Immunogenet. 1998, 26, 1-3.
22. Derynck, R.; Choy, L. Transforming growth factor-beta and its receptors. In The Cytokine Handbook; Thompson, A., Ed.; Academic Press: CA, 1998.
23. Ziv, E.; Cauley, J.; Morin, P.A.; Saiz, R.; Browner, W.S. Association between T29-C polymorphism in the transforming growth factor β1 gene and breast cancer among elderly white women. JAMA 2001, 285, 2859-2863.
24. Xie, W.; Mertens, J.C.; Reiss, D.J.; Rimm, D.L.; Camp, R.L.; Reiss, M. Alerations of smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res. 2002, 62, 497-505.
25. Reiss, M.; Barcellos-Hoff, M.H. Transforming growth factor-β in breast cancer: a working hypothesis. Breast Cancer Res. Treat. 1997, 45, 81-95.
26. Barcellos-Hoff, M.H.; Brooks, A.L. Extracellular sugnaling through the microenvironment: a hypothesis relating carcinogenesis, bystander effects, and genomic instability. Radiat. Res. 2001, 156, 618-627.
27. Grainger, D.J.; Heathcote, K.; Chiano, M.; Snieder, H.; Kemp, P.R.; Metcalfe, J.C.; Carter, N.D.; Spector, T.D. Genetic control of the circulating concentration of transforming growth factor type beat 1. Hum. Mol. Genet. 1999, 8, 93-97.
28. Tang, B.; Bottinger, E.P.; Jakowlew, S.B.; et al. Transforming growth factor-beta 1 is a new form of tumor suppressor with true haploid insufficiency. Nat. Med. 1998, 4, 802-807.
29. Yang, Y.A.; Dukhanina, O.; Tang, B.; Mamura, M.; Letterio, J.J.; MacGregor, J.; Patel, S.C.; Khozin, S.; Liu, Z.Y.; Green, J.; Anver, M.R.; Merlino, G.; Wakefield, L.M. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse effects. J. Clin. Invest. 2002, 109, 1607-1615.
30. Tang, B.; de Castro, K.; Barnes, H.E.; Tony Parks, W.; Stewart, L.; Bottinger, E.P.; Danielpour, D.; Wakefield, L.M. Loss of responsiveness to transforming growth factor beta induces malignant transformation or nontumorigenic rat prostate epithelial cells. Cancer Res. 1999, 59, 4832-4834.
31. Gorelick, L.; Flavell, R.A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nat. Med. 2001, 7, 1118-1122.
32. Cui, W.; Kemp, C.J.; Duffie, E.; Balmain, A.; Akhurst, R.J. Lack of transforming growth factor-beta 1 expression in benign skin tumors of p53 null mice is prognostic for a high risk of malignant conversion. Cancer Res. 1994, 54, 5831-5836.